Wholesale bulk price 100% Pure AsariRadix Et Rhizoma oil Relax Aromatherapy Eucalyptus globulus

short description:

Animal and in vitro studies have investigated the potential antifungal, anti-inflammatory, and cardiovascular effects of sassafras and its components. However, clinical trials are lacking, and sassafras is not considered safe for use. Safrole, the main constituent of sassafras root bark and oil, has been banned by the US Food and Drug Administration (FDA), including for use as a flavoring or fragrance, and should not be used internally or externally, as it is potentially carcinogenic. Safrole has been used in the illegal production of 3,4-methylene-dioxymethamphetamine (MDMA), also known by the street names “ecstasy” or “Molly,” and the sale of safrole and sassafras oil is monitored by the US Drug Enforcement Administration

FOB Price: US $0.5 - 9,999 / Piece

Min.Order Quantity: 100 Piece/Pieces

Supply Ability: 10000 Piece/Pieces per Month

Send email to us

Product Detail

Product Tags

Introduction: Asari radix et rhizoma (Xixin, Manchurian Wildginger, Asarum spp) is a herbal drug commonly used as an ingredient in traditional Chinese medicine (TCM). Many species of Asarum contain safrole and methyleugenol as the main components of their volatile oils. However, toxicological studies have shown that safrole and methyleugenol may be a hepatocarcinogen and/or genotoxic leading to concerns regarding the habitual consumption of this herbal drug.

Materials and methods: An HPLC method was established to assess the levels of safrole and methyleugenol in five batches of Asari radix et rhizoma and two TCM formulae containing this herbal drug as an ingredient. Analyses showed that the content of safrole in the dried herbal drugs tested ranged from 0.14-2.78 mg/ g whilst the content of methyleugenol ranged from 1.94-16.04 mg/g.

Results: The present study demonstrated that following a 1-hour decoction, the amount of safrole was decreased by more than 92% resulting in the equivalent of no more than 0.20 mg/g safrole remaining in the aqueous extract. Similarly, the content of methyleugenol was decreased to the equivalent of 0.30-2.70 mg/g. Furthermore, both TCM formulae, after decoction, showed negligible amounts of safrole (maximum, the equivalent of 0.06 mg/ g), and only 1.38-2.71 mg/g of methyleugenol.

Conclusions: The present study shows that a decoction procedure, similar to that traditionally used for Chinese herbal preparations, is able to effectively reduce the amount of safrole and methyleugenol effectively. Such a reduction in the content of safrole should be acceptable for therapeutic use.